Symptom-oriented network pharmacology revealed the mechanism of HuangQi-DanShen herb pair against cerebral ischemia coupled with comprehensive chemical characterization.

In the clinical practice of traditional Chinese medicine, HuangQi-DanShen (HD) is an important drug pair for the treatment of cerebral ischemia (CI). Elucidate the mechanism of HD against CI based on symptom-oriented network pharmacology coupled with comprehensive chemical characterization. UHPLC-Q-...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Ethnopharmacology Vol. 318
Autores principales: Liu, Yuetao, Xiang, Ruoxin, Lu, Wentian, Qin, Xuemei
Formato: research Journal Article
Publicado: Elsevier B.V. Jan2024:Part A
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=171921075&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 171921075
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        03788741
        3MS
      jtl: Journal of Ethnopharmacology
      issn: 03788741
      maglogo: N
    pubinfo:
      dt: Jan2024:Part A
      vid: 318
      pid: 1004
      pub: Elsevier B.V.
    artinfo:
      ui:
        171921075
        171921075
        171921075
        10.1016/j.jep.2023.116845
        171921075
      ppct: 1
      formats:
      tig:
        atl: Symptom-oriented network pharmacology revealed the mechanism of HuangQi-DanShen herb pair against cerebral ischemia coupled with comprehensive chemical characterization.
      aug:
        au:
          Liu, Yuetao
          Xiang, Ruoxin
          Lu, Wentian
          Qin, Xuemei
        affil: Modern Research Center for Traditional Chinese Medicine, The Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Shanxi University, No. 92, Wucheng Road, Taiyuan, 030006, Shanxi, PR China
      sug:
        subj:
          Network Pharmacology
          Drugs, Chinese Herbal Therapeutic Use
          Medicine, Herbal
          Plant Extracts Pharmacodynamics
          Cerebral Ischemia Drug Therapy
          Chemical Processes Evaluation
          Medicine, Chinese Traditional
          Drug Therapy, Combination
          Epidermal Growth Factor Receptors
          Matrix Metalloproteinases
          Molecular Docking Simulation
          Chromatography, High Pressure Liquid
          Receptors, Cell Surface
          Neurotransmitter Agents
          Gene Expression
          Dyskinesias
          Speech Disorders
          Vision Disorders
      ab: In the clinical practice of traditional Chinese medicine, HuangQi-DanShen (HD) is an important drug pair for the treatment of cerebral ischemia (CI). Elucidate the mechanism of HD against CI based on symptom-oriented network pharmacology coupled with comprehensive chemical characterization. UHPLC-Q-Exactive Orbitrap-MS technology was firstly used to obtain the chemical profile of HD constituents. A comprehensive strategy combining in-house library, diagnostic ions, Compound Discover software and network databases was then established to identify its chemical constitutes. Symptomatic treatment is a treatment aimed at relieving or eliminating symptoms which is often characterized as a stop-gap measure due to its inability to cure the disease fundamentally. Nevertheless, symptomatic treatment is an indispensable part of clinical practice and has an important place in medical therapeutics. Therefore, network pharmacology technique were used to elucidate molecular mechanisms from the symptoms of CI. Finally, some literatures were further mined to support our conclusions. A total of 190 ingredients were identified in HD. Symptom-oriented network pharmacology analysis indicated that compounds of HD relieved "blood" through the regulation of ADORA2A, ADORA1, PTPN11, MMP9 and EGFR, relieved "qi" via the regulation of ADORA2A, EGFR, MMP9 and CA2. The therapeutic effect of HD on "faint" was linked to PTPN11 and MMP9, while the regulation of "dyskinesia" was related to ADORA2A and EGFR, and ADORA1, PTPN11 and MMP9 were associated withe its effect on "speech disorder". ADORA1, ADORA2A and MMP9 were key to the HD component in treating "visual disturbance". The approach of symptom-oriented network pharmacology coupled with comprehensive chemical characterization proposed a further orientation for exploring the mechanisms of HD against CI. [Display omitted] • Symptom-oriented network pharmacology unveiled mechanisms of HD herb pair against CI. • A strategy for compound characterization of HD to aid network pharmacology analysis. • ADORA1, ADORA2A, PTPN11, CA2, EGFR and MMP9 were essential for HD treatment for CI.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N